PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39 th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT / 10:30 a.
|
SOUTH SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT/10:30 a.m. ET.
About PACT Pharma Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, cutting edge (non-viral) precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer. For more information please visit www.pactpharma.com. Media Contact Sarah Sutton Investor Contact Uneek Mehra
SOURCE PACT Pharma |
View original content to download multimedia:
